First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Roviello G, Molina-Cerrillo J, Massari F, Cerbone L, Fiala O, Fornarini G, Monteiro FSM, Cattrini C, Landmesser J, Messina C, Zgura A, Rebuzzi SE, Soares A, Carrozza F, Ansari J, Grillone F, Küronya Z, Incorvaia L, Bhuva D, Ortega C, Nasso C, Kanesvaran R, Zampiva I, Porta C, Buti S, Santoni M.
Roviello G, et al. Among authors: ortega c.
Cancer Immunol Immunother. 2025 Jan 3;74(2):65. doi: 10.1007/s00262-024-03897-x.
Cancer Immunol Immunother. 2025.
PMID: 39752009
Free PMC article.